Akebia Therapeutics
Akebia Therapeutics' revenue rose 47.5% to $236 million in fiscal 2025. Its operating margin was 9.9%, up from −31.5% a year earlier. Free cash flow was $68 million. The diluted share count rose 21.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Akebia Therapeutics does
Akebia Therapeutics is a drug company focused on kidney disease. It sells two products in the United States. Vafseo is a pill, approved by the FDA in March 2024, that treats anemia caused by chronic kidney disease in adults who have been on dialysis for at least three months. Auryxia is a pill that controls phosphorus levels in adults on dialysis and treats iron deficiency anemia in adults with kidney disease who are not on dialysis.
Akebia earns money from sales of both products. Vafseo reached the market in January 2025, and Akebia says it has supply agreements with dialysis organizations that care for nearly 100% of dialysis patients in the U.S. Partners sell Vafseo in some countries outside the United States, and approved use covers adults in 37 countries.
The company also has mid-stage programs for rare kidney diseases and earlier-stage programs, which are not yet approved and need further trials.
Its biggest risks, as it describes them
- Its business depends heavily on selling Auryxia and Vafseo.
- It has lost money since it began and may need more financing, which could dilute owners or restrict it.
- Its loan with BlackRock and its royalty deal with HealthCare Royalty Partners carry strict terms.
- Insurers or government programs may not cover or pay enough for its medicines.
- It may not find, develop or sell additional products.
Income statement
Akebia Therapeutics lost money in fiscal 2025: a net loss of $5 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 150 | 90 | 43 | 52 | 185 |
| Debt incl. finance leases | 98 | 66 | 35 | 39 | 48 |
| Net debt (negative means net cash) | −52 | −24 | −8 | −13 | −137 |
| Net debt to EBITDA | — | — | — | — | −5.5x |
| Debt to equity | 1.3x | — | — | — | 1.5x |
| Interest coverage | −27.5x | −12.0x | −7.6x | −10.0x | 3.9x |
| Current ratio | 1.0x | 1.4x | 1.2x | 1.4x | 1.6x |
| Quick ratio | 0.9x | 1.3x | 1.0x | 1.2x | 1.5x |
Cash flow
Projections
Project Akebia Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $86,588 of Akebia Therapeutics shares on the open market, and 6 insiders sold $962,955, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 29, 2026 | Erik OstrowskiSVP, CFO, CBO & Treasurer | Sold plan | 56,019 | $1.11 | $62,181 | Form 4 |
| Mar 4, 2026 | John P. ButlerCEO and President, Director | Bought | 69,270 | $1.25 | $86,588 | Form 4 |
| Feb 2, 2026 | John P. ButlerCEO and President, Director | Sold plan | 341,305 | $1.39 | $474,414 | Form 4 |
| Feb 2, 2026 | Nicholas GrundChief Commercial Officer | Sold plan | 84,829 | $1.39 | $117,912 | Form 4 |
| Feb 2, 2026 | Carolyn M. RucciSVP, Chief Legal Officer | Sold plan | 69,772 | $1.39 | $96,983 | Form 4 |
| Feb 2, 2026 | Steven Keith BurkeSVP, Chief Medical Officer | Sold plan | 67,658 | $1.39 | $94,045 | Form 4 |
| Feb 2, 2026 | Richard C MalabreSVP, Chief Accounting Officer | Sold plan | 49,524 | $1.39 | $68,838 | Form 4 |
| Feb 2, 2026 | Erik OstrowskiSVP, CFO, CBO & Treasurer | Sold plan | 34,951 | $1.39 | $48,582 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 3 of 9 | 7 of 9 |
| Rule of 40 | −45.5% | −43.1% | 76.1% |
| Altman Z'' | −22.61 | −25.54 | −12.49 |
| Accruals ratio | −9.6% | −12.4% | −24.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 3 of 9 | 3 of 9 | 7 of 9 |
Compare
Put Akebia Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Akebia Therapeutics | FY25 | 47.5% | 9.9% | 28.7% | — | −5.5x | 7 | |
| Puma Biotechnology | FY25 | −0.9% | 16.3% | 18.3% | 48.2% | −1.4x | 8 | Compare |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
| Vanda Pharmaceuticals | FY25 | 8.7% | −70.0% | −51.1% | — | — | — | Compare |
| Amarin | FY25 | −6.5% | −23.5% | — | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 181 | 208 | 335 | 295 | 212 | 292 | 195 | 160 | 236 |
| Revenue growth | — | 11,706.3% | 14.6% | 61.3% | −12.1% | −28.2% | 38.2% | −33.5% | −17.7% | 47.5% |
| Gross profit | — | — | 200 | 190 | −2 | 61 | 207 | 120 | 97 | 197 |
| Research and development | 116 | 231 | 291 | 323 | 218 | 148 | 130 | 63 | 38 | 62 |
| Operating income | −136 | −77 | −178 | −286 | −378 | −264 | −81 | −46 | −50 | 24 |
| Net income | −136 | −74 | −144 | −280 | −385 | −282 | −94 | −52 | −69 | −5 |
| Diluted EPS (US$) | −3.60 | −1.69 | −2.47 | −2.36 | −2.78 | −1.70 | −0.52 | −0.28 | −0.33 | −0.02 |
| Diluted shares (millions) | 38 | 44 | 58 | 118 | 138 | 166 | 183 | 188 | 211 | 257 |
| Cash flow | ||||||||||
| Cash from operations | 58 | −56 | −98 | −257 | −110 | −253 | −73 | −23 | −41 | 68 |
| Capital expenditure | 3 | 2 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 55 | −58 | −99 | −264 | −111 | −253 | −73 | −23 | −41 | 68 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 9 | 19 | 12 | 24 | 23 | 18 | 9 | 8 | 11 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 260 | 318 | 322 | 148 | 269 | 150 | 90 | 43 | 52 | 185 |
| Debt incl. finance leases | — | — | — | 76 | 96 | 98 | 66 | 35 | 39 | 48 |
| Total assets | 300 | 364 | 996 | 771 | 644 | 529 | 356 | 242 | 221 | 377 |
| Total liabilities | 232 | 242 | 361 | 376 | 396 | 455 | 351 | 272 | 270 | 344 |
| Shareholders' equity | 68 | 123 | 636 | 393 | 244 | 74 | 5 | −31 | −49 | 33 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 96.3% | 56.6% | −0.6% | 28.8% | 70.7% | 61.9% | 60.6% | 83.3% |
| Operating margin | −8,889.9% | −42.3% | −85.8% | −85.5% | −128.2% | −125.0% | −27.6% | −23.8% | −31.5% | 9.9% |
| Net margin | −8,843.5% | −40.6% | −69.1% | −83.5% | −130.6% | −133.2% | −32.2% | −26.7% | −43.3% | −2.3% |
| Free cash flow margin | 3,599.0% | −31.9% | −47.7% | −78.8% | −37.6% | −119.5% | −25.1% | −12.0% | −25.4% | 28.7% |
| Rule of 40 (growth + FCF margin) | — | 11,674.4% | −33.1% | −17.6% | −49.6% | −147.7% | 13.1% | −45.5% | −43.1% | 76.1% |
| Return on capital | — | — | — | — | −151.9% | — | — | — | — | — |
| Return on equity | −136.3% | −77.3% | −37.9% | −54.4% | −120.8% | −177.2% | −237.8% | — | — | — |
| Return on assets | −61.3% | −22.2% | −21.1% | −31.6% | −54.4% | −48.1% | −21.3% | −17.4% | −30.0% | −1.8% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | −5.5x |